CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Transtympanic micropressure therapy (Meniett) for Meniere's disease — Coverage Criteria

Policy governing coverage of transtympanic micropressure (Meniett) therapy for treatment of Meniere's disease for Blue Cross Blue Shield - Rhode Island members (Commercial and BlueCHiP for Medicare).

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyTranstympanic micropressure therapy (Meniett) for Meniere's disease — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateFeb 16, 2010

Next Review DateN/A

Key ActionVerify member benefits, eligibility, and applicable subscriber agreement/contract provisions before billing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredMedicare stance

Not medically necessaryCommercial stance

E2120Device code

3x3min/dayTreatment regimen

Coverage Determinations

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage stances

Covered when ALL of the following are met:

BlueCHiP for Medicare stance: Transtympanic micropressure applications as a treatment for Meniere's disease is considered not covered as the evidence is insufficient to determine the effects of the technology on health outcomes.

[[4]]

Commercial products stance: Transtympanic micropressure applications as a treatment for Meniere's disease is considered not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes.

[[5]]

Benefits and coverage for transtympanic micropressure (Meniett) therapy can vary by member plan and contract. Always verify the member's specific benefits, as described in the member Booklet, Evidence of Coverage, or Subscriber Agreement to determine whether a service is covered or considered not medically necessary under that plan.

For Commercial products, transtympanic micropressure therapy (Meniett) is considered not medically necessary because the evidence is insufficient to determine the effects of the technology on health outcomes. The device-specific billing code HCPCS E2120 (pulse generator for tympanic treatment of inner ear endolymphatic fluid system) is listed as not medically necessary / not covered in this policy.

Provider Requirements and Billing Guidance

Prior Authorization

Prior authorization is not applicable for this policy.

Prior authorization: Not applicable

Step Therapy

No step therapy requirements apply for this technology; there are no applicable medical criteria or step edits specified.

Step therapy: None specified

Documentation Required

Benefit Verification and Member Billing

Verify member benefits and eligibility prior to rendering services. Confirm coverage under the member's subscriber agreement or Evidence of Coverage. Obtain informed consent and document member acknowledgement if treating outside of covered benefits or when services are being provided at the member's request and may not be covered.

Verify benefits, eligibility, and subscriber agreement
Obtain informed consent and written agreement before treating when services are not covered or are likely to be denied

Denial Risk

Denial Triggers

Claims may be denied when the technology is not a covered benefit or is considered not medically necessary for the member's product.

BlueCHiP for Medicare: Transtympanic micropressure applications for Meniere's disease — not covered
Commercial Products: Transtympanic micropressure applications for Meniere's disease — not medically necessary

Clinical Background

Meniere's disease is an idiopathic inner ear disorder characterized by episodic vertigo, fluctuating hearing loss, tinnitus, and aural pressure. Transtympanic micropressure (Meniett) therapy delivers intermittent low-frequency pressure pulses via a tympanostomy or ventilation tube using a handheld generator; patients typically self-administer treatments (approximately 3 minutes, three times daily). Systematic reviews and randomized trials have not demonstrated clear benefit over placebo, and the available evidence is considered insufficient to show improved health outcomes.

Definitions and Device Description

Transtympanic micropressure therapy (Meniett)

Device descriptionHand-held air pressure generator (Meniett) that delivers intermittent complex pressure pulses via a conventional ventilation/tympanostomy tube with an external ear‑cuff.

Delivery routePressure pulses delivered through a surgically placed ventilation (tympanostomy) tube into the middle ear; patient uses an ear‑cuff in the external canal.

Typical treatment regimenSelf‑administered: 3 minutes per session, three times daily.

Duration of therapyTreatment is continued for as long as patients experience vertigo attacks (ongoing as needed).

Indication in documentDescribed as a treatment for Meniere's disease to relieve vertigo by applying low‑frequency, low‑amplitude pressure pulses to the middle ear.